Form 4: SeaStar Medical CMO Kevin Chung Reports RSU Vesting and Reclassification of Unvested Equity

SeaStar Medical Holding Corp's Chief Medical Officer, Kevin Chung, reported the vesting of 5,000 restricted stock units and the reclassification of 25,000 unvested RSUs, increasing his direct beneficial ownership to 48,184 shares.

Summary

• Kevin Chung, Chief Medical Officer of SeaStar Medical Holding Corp (ICU), reported a transaction on July 1, 2025.
• 5,000 restricted stock units (RSUs) vested and converted into shares of ICU common stock.
• The transaction price for the acquired shares was $0, which is typical for RSU vesting.
• The filing also reports the reclassification of 25,000 unvested RSU awards, previously reported as derivative securities in Table II, to non-derivative common stock in Table I.
• Following these transactions, Kevin Chung's direct beneficial ownership of common stock is 48,184 shares.
• This total includes the 5,000 newly vested shares and the 25,000 reclassified unvested RSU shares.
• A previous rounding error resulted in a reduction of one share in the reported beneficial ownership.
• The reporting person was granted 15,000 RSUs on November 15, 2024, vesting in three equal annual installments on the first, second, and third anniversaries of July 1, 2024. The 5,000 shares that vested on July 1, 2025, represent the first installment of this grant.

Sentiment

Score: 7

Explanation: The filing indicates a routine, positive event of executive equity vesting and a reporting reclassification, aligning management interests with shareholders. No negative or unexpected elements are present that would suggest a detrimental impact.

Positives

• Vesting of RSUs indicates continued alignment of management's interests with shareholders.
• Increased direct beneficial ownership by a key executive, reinforcing commitment to the company's long-term success.

Future Outlook

The reporting person has additional Restricted Stock Units (RSUs) from the November 15, 2024 grant, which are scheduled to vest in two more equal annual installments on July 1, 2026, and July 1, 2027.

Industry Context

This Form 4 filing is a routine insider transaction, reflecting the vesting of equity compensation and a reclassification of unvested equity for a key executive in the medical device or biotechnology sector. Such transactions are common mechanisms for aligning executive incentives with long-term company performance and shareholder value.

Comparison to Industry Standards

• The vesting of Restricted Stock Units (RSUs) as a form of executive compensation is a standard practice across the biotechnology and medical device industries.
• Companies like Medtronic, Intuitive Surgical, and Boston Scientific frequently utilize RSU grants to incentivize and retain key talent, with vesting schedules typically spanning multiple years.
• The reported transaction aligns with common industry practices for executive equity compensation and ownership structures.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholder value through equity ownership.
• Employees: Reinforces the company's commitment to equity-based compensation for key personnel, potentially boosting morale and retention.

Next Steps

• Future vesting of 5,000 RSUs on July 1, 2026.
• Future vesting of 5,000 RSUs on July 1, 2027.

Key Dates

Recommendation

Keywords

SeaStar Medical Holding Corp, ICU, Kevin Chung, Chief Medical Officer, Form 4, SEC filing, Restricted Stock Units, RSU vesting, insider transaction, beneficial ownership, equity compensation